Activating mutations of
anaplastic lymphoma kinase (ALK) have been identified as important players in
neuroblastoma development. Our goal was to evaluate the significance of overall ALK activation in
neuroblastoma. Expression of phosphorylated ALK, ALK, and its putative
ligands,
pleiotrophin and
midkine, was screened in 289
neuroblastomas and 56 paired normal tissues. ALK was expressed in 99% of
tumors and phosphorylated in 48% of cases.
Pleiotrophin and
midkine were expressed in 58% and 79% of
tumors, respectively. ALK activation was significantly higher in
tumors than in paired normal tissues, together with ALK and
midkine expression. ALK activation was largely independent of mutations and correlated with
midkine expression in
tumors. ALK activation in
tumors was associated with favorable features, including a younger age at diagnosis, hyperdiploidy, and detection by mass screening. Antitumor activity of the ALK inhibitor
TAE684 was evaluated in wild-type or mutated ALK
neuroblastoma cell lines and xenografts.
TAE684 was cytotoxic in vitro in all cell lines, especially those harboring an ALK mutation.
TAE684 efficiently inhibited ALK phosphorylation in vivo in both F1174I and R1275Q xenografts but demonstrated antitumor activity only against the R1275Q xenograft. In conclusion, ALK activation occurs frequently during
neuroblastoma oncogenesis, mainly through mutation-independent mechanisms. However, ALK activation is not associated with a poor outcome and is not always a driver of cell proliferation and/or survival in
neuroblastoma.